Julita Kulbacka
Overview
Explore the profile of Julita Kulbacka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
2159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gachowska M, Dabrowska A, Wilczynski B, Kuznicki J, Sauer N, Szlasa W, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596429
Xenoestrogens (XEs) are a group of exogenous substances that may interfere with the functioning of the endocrine system. They may mimic the function of estrogens, and their sources are plants,...
12.
Rembialkowska N, Kucharczyk J, Radzeviciute-Valciuke E, Novickij V, Tonci M, Dundar A, et al.
Biomed Pharmacother
. 2024 Nov;
181:117691.
PMID: 39557010
Calcium electroporation (CaEP) involves the combination of calcium ions with electroporation, which is induced by pulsed electric fields (PEFs). This study explores the application of high-frequency unipolar nanosecond pulsed electric...
13.
Wezgowiec J, Malysa A, Szlasa W, Kulbacka J, Chwilkowska A, Zietek M, et al.
Front Bioeng Biotechnol
. 2024 Nov;
12:1453888.
PMID: 39534672
Objectives: The development of additive manufacturing has the potential to revolutionize the fabrication of medical devices. This technology, also known as 3D printing, offers precise, cost-effective, and personalized approaches, which...
14.
Szlasa W, Sauer N, Karwacki J, Szewczyk A, Kulbacka J, Szydelko T, et al.
Dent Med Probl
. 2024 Oct;
61(5):713-720.
PMID: 39480959
Background: Avelumab is a human antibody that targets the programmed cell death ligand-1 (PD-L1) protein in cancer cells. Novel anticancer therapies for renal cell carcinoma (RCC) consider cluster of differentiation...
15.
Jarocki M, Turek K, Saczko J, Tarek M, Kulbacka J
Cell Death Discov
. 2024 Oct;
10(1):460.
PMID: 39477959
Autophagy is a molecular process essential for maintaining cellular homeostasis, with its impairment or dysregulation linked to the progression of various diseases in mammals. Specific lipids, including phosphoinositides, sphingolipids, and...
16.
Zaitsava H, Gachowska M, Bartoszewska E, Kmiecik A, Kulbacka J
Molecules
. 2024 Oct;
29(20).
PMID: 39459201
Nuclear pore complexes (NPCs) play a critical role in regulating transport-dependent gene expression, influencing various stages of cancer development and progression. Dysregulation of nucleocytoplasmic transport has profound implications, particularly in...
17.
Lekesyte B, Mickeviciute E, Malakauskaite P, Szewczyk A, Radzeviciute-Valciuke E, Malysko-Ptasinske V, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458609
Electrochemotherapy (ECT) is a safe and efficient method of targeted drug delivery using pulsed electric fields (PEF), one that is based on the phenomenon of electroporation. However, the problems of...
18.
Choromanska A, Szwedowicz U, Szewczyk A, Daczewska M, Saczko J, Kruszakin R, et al.
Biochim Biophys Acta Gen Subj
. 2024 Oct;
1868(12):130723.
PMID: 39426760
Although the pulse electric field (PEF) has been used in electrochemotherapy (ECT) for many years, the kinetics and profile of extracellular particles (EPs) released as a result of reversible electroporation...
19.
Wilczynski B, Dabrowska A, Kulbacka J, Baczynska D
Cell Commun Signal
. 2024 Oct;
22(1):486.
PMID: 39390572
Resistance of cancer cells to anticancer drugs remains a major challenge in modern medicine. Understanding the mechanisms behind the development of chemoresistance is key to developing appropriate therapies to counteract...
20.
Przystupski D, Baczynska D, Rossowska J, Kulbacka J, Ussowicz M
Biomed Pharmacother
. 2024 Oct;
180:117442.
PMID: 39366835
No abstract available.